A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)

Study Summary

This is a study to assess the pharmacokinetics, safety, and tolerability of pembrolizumab formulated with berahyaluronidase when administered as a SC injection to participants with advanced solid tumors. Participants will receive SC injections of pembrolizumab (+) berahyaluronidase alfa containing one of 2 different concentrations (Conc) of pembrolizumab, Conc1 and Conc2, corresponding to a pembrolizumab dose level of dose 1 for Arms 1, 2, and 3 and dose 2 for Arm 4.

Conditions

Advanced or Metastatic Solid Tumors

Interventions / Drugs

Pembrolizumab (+) Berahyaluronidase alfa Pembrolizumab Pemetrexed Carboplatin Paclitaxel Nab-paclitaxel Axitinib Cisplatin

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment72 participants

Primary Completion—

Lead SponsorMerck Sharp & Dohme LLC

Data Retrieved2026-04-11 02:55:36.205423+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.